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ABSTRACT:
Limited improvement in long term survival of lung cancer patients has been 
achieved by conventional chemotherapy or targeted therapy. To explore the potentials 
of tumor initiating cells (TIC)-directed therapy, it is essential to identify the cell targets 
and understand their maintenance mechanisms. We have analyzed the performance of 
ALDH/CD44 co-expression as TIC markers and treatment targets of lung cancer using 
well-validated in vitro and in vivo analyses in multiple established and patient-derived 
lung cancer cells. The ALDHhiCD44hi subset showed the highest enhancement of stem 
cell phenotypic properties compared to ALDHhiCD44lo, ALDHloCD44hi, ALDHloCD44lo 
cells and unsorted controls. They showed higher invasion capacities, pluripotency 
genes and epithelial-mesenchymal transition transcription factors expression, lower 
intercellular adhesion protein expression and higher G2/M phase cell cycle fraction. 
In immunosuppressed mice, the ALDHhiCD44hi xenografts showed the highest tumor 
induction frequency, serial transplantability, shortest latency, largest volume and 
highest growth rates. Inhibition of sonic Hedgehog and Notch developmental pathways 
reduced ALDH+CD44+ compartment. Chemotherapy and targeted therapy resulted 
in higher ALDHhiCD44hi subset viability and ALDHloCD44lo subset apoptosis fraction. 
ALDH inhibition and CD44 knockdown led to reduced stemness gene expression and 
sensitization to drug treatment. In accordance, clinical lung cancers containing a 
higher abundance of ALDH and CD44-coexpressing cells was associated with lower 
recurrence-free survival. Together, results suggested the ALDHhiCD44hi compartment 
was the cellular mediator of tumorigenicity and drug resistance. Further investigation 
of the regulatory mechanisms underlying ALDHhiCD44hi TIC maintenance would be 
beneficial for the development of long term lung cancer control. 
INTRODUCTION
Lung cancer is the most common malignancy but 
curative therapy for metastatic disease is limited. Although 
tyrosine kinase inhibitor (TKI) therapy achieves a higher 
objective response rate and longer progression free 
survival in cancers with epidermal growth factor receptor 
(EGFR) mutations or anaplastic lymphoma kinase (ALK)-
rearrangement, relapse is the rule after 10-14 months 
due to drug resistance [1-5]. Increasing evidences have 
shown in many cancers, enhanced tumorigenicity resides 
in a tumor cell population that exhibits stem cell-like 
properties such as self-renewal, differentiation, cell 
mobility and toxicity resistance, designated as cancer 
stem cells (CSC) or tumor initiating cells (TIC) [6, 7]. 
Inhibition of morphogenesis regulatory pathways such the 
Hedgehog, Notch and Wnt/β-catenin pathways can retard 
tumor transplantability, further supporting TIC-targeting 
could be useful for lung cancer control [8-11]. However, a 
deeper understanding of the cell targets and maintenance 
mechanisms is essential for further therapy development.
Lung cancer cells expressing various molecules such 
as CD133, CD166, ALDH, CXCR4, GLDC, etc. have 
been shown to demonstrate TIC phenotypic characteristics 
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[12-15]. On the other hand, to identify TIC with higher 
specificity, more stringent selection strategies such as the 
adoption of co-expressed markers and verification in larger 
numbers of cell lines including patient-derived samples 
are advocated. We have previously demonstrated lung 
cancer cells with high CD44 expression were enriched 
for stem cell-like properties [16]. Moreover, CD44 is 
expressed in breast, colon and gastric cancer stem cells 
[17-19]. Aldehyde dehydrogenase 1 (ALDH) is expressed 
in murine embryonic lungs and has been reported to 
select for human lung TIC [15, 20, 21]. The specificity 
of combined ALDH/CD44 expression as lung TIC marker 
compared to either marker alone is not known. In this 
study, we have used a range of established and patient-
derived lung cancer cell lines (PDCL) to show cells with 
high ALDH and CD44 co-expression (ALDHhiCD44hi) 
possessed in vitro and in vivo TIC properties with 
enhanced tumorigenicity and drug resistance compared to 
the low-expressing (ALDHloCD44lo) compartment or un-
selected cells. Simultaneous ALDH inhibition and CD44 
depletion as well as pharmacologic inhibition of Hedgehog 
or Notch attenuated TIC characteristics. In clinical lung 
cancers, recurrence-free survival was longer for patients 
with low abundance ALDH/CD44-coexpressing cells (p 
= 0.053). Our data demonstrated lung TIC are enhanced 
through ALDH and CD44 co-regulating pathways. Further 
investigation of the ALDHhiCD44hi population would 
enable a better understanding of TIC regulation and 
facilitate development of therapeutic strategies for long 
term lung cancer control.
RESULTS
ALDHhiCD44hi population displayed in vitro TIC 
properties
The ALDH/CD44 co-expression profiles of 11 
lung cancer cell lines including PDCL and drug-induced 
resistant cells were analyzed by flow cytometry. In 6 
cell lines, ALDH/CD44 co-expressing cells (ALDH+/
CD44+) comprised the smallest subset with ALDH/
CD44 non-expressing cells (ALDH-/CD44-) forming 
the largest population (Supplementary Table S1). 
Subsequently, the top/bottom 1 to 5% of cells showing 
highest/lowest expression of the markers (ALDHhiCD44hi, 
ALDHhiCD44lo, ALDHloCD44hi and ALDHloCD44lo) were 
freshly isolated from H1650 and HCC827 cell lines for 
further in vitro tests. In the spheroid formation assay, the 
ALDHhiCD44hi populations generated more abundant 
and larger spheroid bodies than the other 3 subsets 
(Figure 1A). In the cell invasion assay, they demonstrated 
the highest percentage of invading cells while the 
ALDHloCD44lo subset showed the lowest (Figure 1B). In 
vitro differentiation in normal culture conditions showed 
only the ALDHhiCD44hi subset was able to differentiate 
into all 4 cell populations with similar distribution profile 
as the parental cell line while compositions of the other 3 
subsets remained largely unchanged from their fresh, post-
sorting profiles (Figure 1C). 
The ALDHhiCD44hi population showed expression 
profiles that were characteristic of TIC. They had 
significantly higher expression of the pluripotency genes 
NANOG, POU5F1 and SOX2 at both the mRNA and 
protein levels compared to ALDHloCD44lo and unsorted 
populations (Figure 1D to F). They also showed higher 
mRNA expression of the epithelial to mesenchymal 
transition (EMT) transcription factors ZEB1 and SNAIL2, 
the mesenchymal gene VIM, the DNA double strand break 
repair gene RAD51, the TGFβ/IL6 axis gene IL6ST, and 
a lower expression level of the cell adhesion molecule 
CDH1 (Figure 1D & E).
ALDHhiCD44hi showed G2/M shift compared to 
ALDHloCD44lo subset in cell cycle analysis
Cell cycle analysis showed the ALDHhiCD44hi subset 
of H1650 had a significantly higher proportion in G2/M 
phase (14.57 ± 3.23%) compared to ALDHloCD44lo (3.74 ± 
0.59%, p < 0.05) and unsorted controls (5.81 ± 0.23%, p < 
0.01) while cells in G0/1 phase were less abundant (48.42 
± 4.48%) than the other populations (ALDHloCD44lo, 
71.84 ± 2.58%, p < 0.01; unsorted, 72.06 ± 9.98%, p < 
0.05) (Figure 1G). Cell growth kinetics analysis showed 
a higher growth rate of ALDHhiCD44hi than unsorted 
and ALDHloCD44lo cells (Figure 1H). Correspondingly, 
the mRNA expression of the G2/M phase cell cycle 
genes CCNB1 and CCNB2 were significantly higher in 
ALDHhiCD44hi than either ALDHloCD44lo or unsorted 
cells (Figure 1I). 
ALDHhiCD44hi subset showed the highest 
tumorigenicity in immunosuppressed mice
To test for in vivo tumorigenicity, the 4 freshly 
harvested ALDH/CD44 populations and unsorted 
controls were transplanted subcutaneously into SCID 
mice according to their assigned locations (Figure 2A & 
B) from 3 established cell lines and 4 PDCLs. As shown 
in Table 1, the ALDHhiCD44hi population of all analyzed 
cell lines demonstrated higher graft rates, shorter latency 
and larger volumes of xenografts compared to the same 
dose of ALDHloCD44hi, ALDHhiCD44lo or ALDHloCD44lo 
cells (Figure 2C & D). As few as 500 ALDHhiCD44hi cells 
of HCC827 or H1650 but not other populations were able 
to initiate tumors at this low seeding dose (Supplementary 
Table S2). Interestingly, the HKULC3 cell line, which did 
not form xenografts from 108 unsorted cells transplanted 
in nude mice for 6 months in our previous study, was able 
to initiate tumor in SCID mice from 4,000 ALDHhiCD44hi 
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cells in 3 months ([22] , Table 1).
Serial transplantation showed ALDHhiCD44hi–
derived tumors had increasing induction frequencies, 
reduced latency and increased growth rates in 
successive generations compared to the first-generation 
transplants (Table 1, Figure 2E & F). In contrast, the 
tumor frequencies of ALDHloCD44hi, ALDHhiCD44lo, 
ALDHloCD44lo or unsorted cells decreased in the second 
and tertiary generations (Table 1).
Figure 1: ALDHhiCD44hi lung cancer cells showed in vitro TIC characteristics. A, Spheroid formation assay. FACS-isolated 
lung cancer cell populations with differential ALDH/CD44 expressions and unsorted cell controls were kept in serum-free non-adherent 
plates for 21 days. B, Matrigel invasion assay. The proportions of invading cells from respective cell subsets were normalized to the 
unsorted control. C, In vitro differentiation assay. The 4 freshly isolated populations were separately cultured in adhesive plates containing 
normal medium for 2 weeks. Cells were then freshly harvested and re-analyzed by flow cytometry for ALDH/CD44 expression profile. The 
central profile represented parental unsorted cells and profiles of the subsets were as labeled. D and E, Normalized mRNA expressions of 
pluripotency, EMT and other genes by QPCR. F, Pluripotency proteins expression analyzed by flow cytometry. Results were normalized 
to unsorted control. G, Cell cycle analysis. Freshly isolated ALDHhiCD44hi and ALDHloCD44lo populations of H1650 were stained with 
propidium iodide and analyzed by flow cytometry for DNA content. H, Cell proliferation assay. Respective subsets of freshly isolated 
H1650 cells were analyzed by MTT. I, Expression of CCNB1 and CCNB2 analyzed by QPCR.*, p < 0.05; **, p < 0.01; ***, p < 0.001, 
compared with unsorted; #, p < 0.05; ##, p < 0.01; ###, p < 0.001, compared with ALDHhiCD44hi. All data represent the mean ± SD of 
triplicate experiments.
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ALDHhiCD44hi population showed in vitro and in 
vivo resistance to anti-cancer drugs
The response of ALDH/CD44 subsets to both 
targeted drugs and cytotoxic chemotherapy were 
compared using in vitro and in vivo models. Gefitinib 
treatment of the TKI-sensitive HCC827 (EGFR exon19 
deletion) led to significant elevation of ALDH+CD44+ and 
ALDH+CD44- subsets (Figure 3A). In cells induced by 
chronic exposure to increasing gefitinib dosage (HCC827-
GR), progressive resistance was associated with stepwise 
increase in ALDH+CD44+ proportions (Figure 3B). This 
population was also higher in HCC827 induced for 
cisplatin-resistance (HCC827-CR) (Figure 3C). Cell 
viability to gefitinib treatment was significantly higher 
for ALDHhiCD44hi compared to unsorted HCC827 cells 
(Figure 3D). Conversely, the apoptotic fractions after 
24 hrs cisplatin treatment were significantly higher in 
ALDHloCD44lo (p < 0.05) and unsorted H1650 cells (TKI-
resistant, cisplatin-sensitive) (p < 0.01) while no effect was 
observed in the ALDHhiCD44hi population (Figure 3E). 
Amongst 5 TKI-treated mice bearing HCC827 xenografts, 
only ALDHhiCD44hi-derived tumors persisted after 4-5 
Figure 2: ALDHhiCD44hi population showed TIC properties in vivo. A, Schematic diagram showing transplantation sites 
of respective ALDH/CD44 populations in SCID mice. B, Representative photographs of H1650 or HCC827 xenografts derived from 
respective ALDH/CD44 populations after 3 months tumor development. C and D, Tumor growth curves of 1st generation xenografts derived 
from 2,500 cells of respective ALDH/CD44 populations. E and F, tumor growth curves of 3 serially transplanted generations of xenografts 
derived from 2,500 ALDHhiCD44hi cells of respective cell lines. Data represent the mean ± SD of tumor volumes at different time points of 
different groups, there are 6 mice in each group. 
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weeks intraperitoneal gefitinib while no residual tumor 
was detected histologically at other injection sites (Figure 
3F & 3G). No reduction in tumor size was observed in 
mice receiving control treatment.
Hedgehog and Notch pathway inhibition 
suppressed ALDHhiCD44hi and spheroid 
formation
To investigate whether morphogenesis pathways 
Table 1: Serial transplantation of ALDH/CD44 subsets from different NSCLC cell lines
Cell line and subset
1st generation 2nd generation 3rd generation
Tumor incidence Latency (days) Tumor incidence Latency (days)
Tumor 
incidence Latency (days)
H1650 2,500 cells injection 2,500 cells injection 2,500 cells injection
Unsorted 3/6 69.6 ± 5.6 0/5 N/A ND ND
ALDHloCD44lo 2/6 75.0 ± 4.0 1/6 89 1/6 90
ALDHloCD44hi 3/6 72.7 ± 6.7 4/6 64.0 ± 10.8 3/5 35.3 ± 1.0
ALDHhiCD44lo 4/6 43.5 ± 2.5 5/6 53.4 ± 3.8 4/5 50.8 ± 1.3
ALDHhiCD44hi 6/6 41.0 ± 5.0 6/6 25.8 ± 2.0 6/6 19.0 ± 1.8
HCC827 2,500 cells injection 2,500 cells injection 2,500 cells injection
Unsorted 2/3 42.7 ± 2.9 3/4 60.0 ± 11.1 0/4 N/A
ALDHloCD44lo 1/3 59 2/4 65.5 ± 4.9 0/4 N/A
ALDHloCD44hi 2/3 41.0 ± 2.0 3/3 63.0 ± 6.9 1/4 43
ALDHhiCD44lo 2/3 41.0 ± 7.5 4/4 53.3 ± 9.5 2/4 44.5 ± 2.1
ALDHhiCD44hi 3/3 29.0 ± 1.0 4/4 22.0 ± 1.6 4/4 20.2 ± 1.8
PDCL #24 30,000 cells injection 2,500 cells injection 2,500 cells injection
Unsorted 3/3 22.0 ± 1.2 1/3 44.0 1/3 50.0
ALDHloCD44lo 2/3 33.5 ± 2.0 1/3 44.0 0/3 N/A
ALDHloCD44hi 3/3 22.0 ± 1.2 3/3 34.0 ± 1.0 2/3 45.2 ± 3.7
ALDHhiCD44lo N/A N/A 0/2 N/A N/A N/A
ALDHhiCD44hi 3/3 8.7 ± 1.5 3/3 20.7 ± 2.1 3/3 18.7 ± 3.2
PDCL #2 8,000 cells injection 8,000 cells injection ND
Unsorted 0/3 N/A 0/3 N/A ND ND
ALDHloCD44lo 0/3 N/A 0/3 N/A ND ND
ALDHloCD44hi 0/3 N/A 0/3 N/A ND ND
ALDHhiCD44lo 0/3 N/A 0/3 N/A ND ND
ALDHhiCD44hi 2/3 150.0 ± 42.4 3/3 39.0 ± 1.7 ND ND
PDCL #10 1,500 cells injection 1,200 cells injection 600 cells injection
Unsorted 0/3 N/A 0/3 N/A ND ND
ALDHloCD44lo 0/3 N/A 0/3 N/A ND ND
ALDHloCD44hi 3/3 20.0 ± 5.0 0/3 N/A 0/3 N/A
ALDHhiCD44lo 0/3 N/A 0/3 N/A 0/3 N/A
ALDHhiCD44hi 3/3 9.0 ± 2.0 3/3 12.0 ± 3.0 3/3 52.1 ± 8.5
PDCL #18 10,000 cells injection ND ND
Unsorted 0/2 N/A ND ND ND ND
ALDHloCD44lo 0/2 N/A ND ND ND ND
ALDHloCD44hi 1/2 35.0 ND ND ND ND
ALDHhiCD44lo 0/2 N/A ND ND ND ND
ALDHhiCD44hi 2/2 17.0 ± 4.0 ND ND ND ND
HKULC3 4,000 cells injection 4,000 cells injection ND
Unsorted 0/3 N/A ND ND ND ND
ALDHloCD44lo 0/3 N/A ND ND ND ND
ALDHloCD44hi 0/3 N/A ND ND ND ND
ALDHhiCD44lo 0/3 N/A ND ND ND ND
ALDHhiCD44hi 3/3 92.3 ± 4.0 3/3 76.3 ± 6.9 ND ND
N/A, tumor dimension not available; ND, not done
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were involved in ALDHhiCD44hi subset maintenance, the 
effects of pharmacological inhibition of Hedgehog and 
Notch pathways were analyzed. The expression of sonic 
Hedgehog (SMO, GLI1) and Notch (NOTCH1, NOTCH3, 
HEY1) pathway genes were significantly higher in 
ALDHhiCD44hi compared to ALDHloCD44lo populations in 
both H1650 and HCC827 (Figure 4A & B). Cyclopamine 
treatment led to mRNA suppression of the Hedgehog 
transcription factor GLI1 by >50% while RO4929097 
suppressed the Notch transcription factor HES1 by 30%, 
respectively (Figure 4C). These treatments resulted in 
reduction of the ALDH+CD44+ in both cell lines as well as 
inhibited spheroid formation, indicating their involvement 
in ALDHhiCD44hi subset maintenance (Figure 4D to 4F).  
CD44 knockdown and ALDH inhibition sensitized 
tumor cells to in vitro anti-cancer drugs 
To investigate the role of ALDH and CD44 in TIC 
maintenance, ALDH enzymatic activity was completely 
inhibited by DEAB and CD44 was down-regulated with 
80-90% reduction in mRNA and protein expression 
in multiple cancer cell lines (Figure 5A & B). These 
treatments led to a variable reduction of developmental 
regulatory genes expression by 30-50% including 
Figure 3: ALDHhiCD44hi cells showed drug resistance in vitro and in vivo. A, Effects of 30 nM gefitinib treatment for 24 hr 
on ALDH/CD44 subsets of HCC827 analyzed by flow cytometry. B and C, Proportions of ALDH+CD44+ and ALDH-CD44- cells in drug-
resistant HCC827 cells. Resistance was induced by chronic exposure to increasing gefitinib doses (HCC827-GR) or to cisplatin (HCC827-
CR). D, In vitro cell viability response. Freshly isolated ALDHhiCD44hi and unsorted cells of HCC827 were treated with a range of gefitinib 
doses for 24 hr and cell viability was assayed by MTT. E, Apoptosis response. Freshly isolated respective populations and unsorted 
H1650 were treated with 5 µM cisplatin for 24 hr and apoptosis fractions were assayed by Annexin V/PI staining. F, In vivo xenograft 
response after TKI treatment. Mice bearing HCC827 xenografts from respective ALDH/CD44 subsets as depicted in Figure 2A were given 
intraperitoneal gefitinib 5 times per week for 5 weeks. G, In vivo tumor response curve. Tumor volumes of respective HCC827 xenografts 
in TKI-treated (n = 5) or control-treated (n = 3) mice were measured twice weekly. Data represent mean ± SD of tumor volume normalized 
to pre-treatment size in gefitinib-treated mice. *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with control treatment or unsorted cells.
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POU5F1, NANOG, SOX2 and BMI1 (Figure 5A & B). 
It also resulted in significant sensitization to cisplatin 
(H1299, H1650, PDCL #24, p < 0.05) and gefitinib 
treatment ((HCC827-GR, p < 0.01; H1650-GR, p < 0.001) 
with reduced cell viability (Figure 5C).
Lung cancer patients with lower abundance of 
tumor cells co-expressing ALDH and CD44 had 
longer recurrence-free survival
Immunohistochemical analysis of 193 resected 
Figure 4: Hedgehog and Notch signaling were involved in ALDHhiCD44hi TIC maintenance. A and B, mRNA levels of 
Hedgehog and Notch signaling genes by QPCR in sorted cells from H1650 and HCC827. C, mRNA levels of HES1 or GLI1 by QPCR 
in HCC827 after Notch inhibition by RO4929097 or Hedgehog inhibition by cyclopamine. D and E, Proportions of ALDH+CD44+ by 
flow cytometry in HCC827 and H1650 after pathway inhibition for 1 or 4 days. F, Spheroid formation assay of HCC827 cells treated 
with inhibitors. *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with unsorted or control; #, p < 0.05; ##, p < 0.01, compared with 
ALDHhiCD44hi. Data represent mean ± SD of triplicate experiments.
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Figure 5: CD44 knockdown and ALDH inhibition reduced pluripotency gene expression and sensitized cells to drug 
treatment. A and B, mRNA and protein expressions of CD44 and pluripotency genes. CD44 was depleted by siRNA and ALDH inhibited 
by DEAB (100 µM) in H1299, H1650 and PDCL #24, control siRNA and Ethanol were used as control. Histograms represent mean ± SD 
of mRNA measured by QPCR in triplicates and protein expression was analyzed by western blot. C, Cell viability assay. CD44 and ALDH-
inhibited or control cells were treated respectively with cisplatin (H1650, 10 µM; H1299 & PDCL #24, 15 µM) or gefitinib (HCC827 GR, 
10 µM; H1650 GR, 20 µM) for 24 hrs. *, p < 0.05; **, p < 0.01; ***, p < 0.001, compared with control. Data represent mean ± SD of 
triplicate experiments. 
Figure 6: ALDH and CD44 expression in clinical lung cancers. A to D, ALDH/CD44 co-expression patterns were variable in 
different tumors. A and B, Cytoplasmic ALDH expression (A) was observed in only a few tumor cells (→) at the invasion front of this 
squamous cell carcinoma while membranous CD44 expression (B) was present in all tumor cells in the same cluster. Co-localizing cells 
showing both ALDH and CD44 expression were few and thus graded as low abundance. C and D, This adenocarcinoma showed co-
expression of ALDH (C) and CD44 (D) in almost all tumor cells and was thus graded as high abundance. E to G, Kaplan Meier survival 
curves comparing recurrence-free survival (RFS) in different tumor groups. For single marker analysis of ALDH (E) or CD44 (F), no 
significant difference in RFS was observed between tumor groups showing low or high abundance. For ALDH/CD44 dual marker analysis 
(G), RFS was shorter for patients with high compared to low abundance ALDH/CD44-coexpressing TIC (p = 0.053). 
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lung cancers of mixed histological types showed 
ALDH was expressed in 82 (42.5%) and CD44 in 119 
(61.7%) cases, respectively (Supplementary Table S4). 
ALDH and CD44 expression were both associated with 
squamous cell carcinomas (χ2 test, p = 0.035 and p = 
0.005, respectively). No association of either marker 
with tumor differentiation, pathological stage, patient 
gender or smoking history was found. There was no 
correlation between cases that showed ALDH and 
CD44 expression. Clinicopathological variables such as 
gender, smoking history, age, pathological stage, tumor 
type, differentiation, and ALDH or CD44 single marker 
expression were included in Cox regression multivariate 
analysis for recurrence-free survival (RFS), and results 
showed the male gender (HR 2.89, 95% CI 1.48-5.63, p = 
0.002) and advanced pathological stage (HR 1.96, 95% CI 
1.50-2.56, p < 0.001) were independent prognostic factors 
associated with shorter RFS. 
In 43 (22.3%) tumors, neither ALDH nor CD44 
was expressed. In 47 (24.4%) cases, ALDH/CD44 co-
expressing cells were detected, including 27 (57.4%) 
showing only a few scattered co-expressing cells (low 
abundance) and 20 (42.6%) cases that showed large 
aggregates or confluent sheets of such tumor cells 
(high abundance) (Figure 6A to D). In this group, 
survival analysis by log rank test showed there was no 
association between RFS and ALDH or CD44 single 
marker expression (Figure 6E & F). However, the low 
abundance ALDH/CD44 co-expressing group had longer 
RFS than the high abundance group (p = 0.053) (Figure 
6G). The effect on overall survival did not reach statistical 
significance (p = 0.141). 
DISCUSSION
Cellular heterogeneity encompassing a TIC 
population that carries enhanced tumorigenic potentials has 
been demonstrated in many cancers but the mechanisms 
maintaining such populations remain unclear. To study the 
regulatory mechanisms, the distinction of TIC from non-
TIC is required but opinions differ on the most appropriate 
method of TIC identification. Some investigators employ 
the cell spheroid as an in vitro functional TIC indicator but 
the TIC purity, particularly of large spheroids, has seldom 
been documented and its applicability in mechanistic 
studies is unclear. On the other hand, the employment 
of cell surface markers allows the in vitro isolation of a 
particular cell population but no single marker has been 
found to be universally applicable for all cancers and the 
specific scenario being investigated needs to be noted. In 
this study, we have employed a series of well-validated 
in vitro, in vivo and expression assays to demonstrate the 
association of TIC properties with the ALDHhiCD44hi 
phenotype in a panel of established lung cancer cell lines 
as well as PDCL. Transplantation studies using multiple 
cell lines and PDCL consistently showed tumors derived 
from ALDHhi/CD44hi cells had the highest tumor induction 
and growth rate, lowest seeding dose, and shortest latency 
in immunodeficient mice that could be serially passaged 
for at least 3 generations. Early passage PDCL which are 
generally believed to be less adapted to in vitro growth 
conditions could be serially transplanted through the 
ALDHhiCD44hi subset but much less readily through the 
other 3 populations. Compared to CD44 or ALDH single 
marker, tumorigenicity was enhanced in cells selected by 
ALDHhiCD44hi combined marker ([16] and Supplementary 
Table S3). Moreover, the ALDH+CD44+ population and 
cell spheres formation were inhibited by pharmacological 
disruption of developmental programs such as the sonic 
Hedgehog and Notch pathways. The results of these 
comprehensive assays showed under de novo experimental 
conditions, tumor cells showing the highest expression of 
ALDHhiCD44hi combined markers demonstrated enhanced 
TIC properties. This marker combination has also been 
shown to associate with TIC potentials in head and neck 
as well as breast cancers [23, 24]. 
Interestingly, results of in vitro differentiation 
studies were consistent with the expected identity of 
ALDHhiCD44hi population as TIC as it yielded 4 progenies 
distributed in proportions resembling the parental cell 
line while the others remained largely as the original 
phenotype lacking differentiation capacity. However, 
in the xenografts, tumors derived from all populations 
including ALDHloCD44lo showed similar ALDH/CD44 
profiles (data not shown). This could be due to phenotypic 
plasticity with conversion of non-TIC into TIC under 
tumor microenvironment stimulation. Experimentally, 
the TGFβ/IL6 axis has been proposed to be involved 
in CSC maintenance. We found that exogenous TGFβ 
stimulation of HCC827 induced a significant increase 
of ALDH+CD44+ cells from 3.63% to 9.38% (p < 0.05) 
(Supplementary Figure S1). TGFβ is shown to be involved 
in CD44 regulation in breast CSC maintenance while 
interleukin 6 (IL6) can promote growth and survival of 
glioma stem cells [25, 26]. These data not only caution 
against a purely in vitro approach in studying TIC 
regulation but also indicate disrupting stroma-cancer 
interactions is important in anti-TIC therapy. 
One of the major implications of the CSC theory 
is that chemotherapy or target therapy effects are mainly 
incident on the non-TIC thus compromising long term 
cancer control [27-29]. Our in vitro and in vivo results 
argue in favor of this hypothesis. The IC50 of gefitinib 
was almost 8.5 fold higher for TIC than unsorted cells 
of HCC827, while cisplatin produced higher apoptotic 
rate in non-TIC than TIC of H1650 (Figure 3). Only 
subcutaneous xenografts derived from ALDHhiCD44hi 
progenies persisted after intraperitoneal gefitinib 
injection. The mechanism mediating the differential drug 
resistance is likely to be multifactorial. In both animal 
and human studies, ALDH mediates detoxification 
and cyto-protection against multiple agents such as 
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aldehydes, alkylating drugs, oxidative stress, etc. On the 
other hand, through the retinoid signaling pathway, it is 
involved in self-renewal and tissue differentiation [30, 
31]. For CD44, binding to hyaluronan increases NANOG 
phosphorylation and nuclear translocation, subsequently 
leading to the upregulation and stabilization of multidrug-
resistant protein 1 (MDR1) for drug export [32]. CD44 
interaction with POU5F1-SOX2-NANOG signaling also 
plays a pivotal role in CSC maintenance from head and 
neck cancers [33]. Together, these date suggest ALDH and 
CD44 could mediate drug-resistance directly or through 
stem cell regulatory programs. Indeed, in our study, 
concomitant CD44 depletion and ALDH inhibition led to 
sensitization of resistant cells to gefitinib and cisplatin, as 
well as down-regulation of pluripotency genes NANOG, 
SOX2 and POU5F1. 
Other potential mechanisms enhancing 
tumorigenicity and drug resistance of the ALDHhiCD44hi 
TIC include a higher G2/M fraction, elevated cyclin 
B1 and B2 expression and correspondingly, a higher 
population growth rate. This population also showed 
elevated expression of the double strand break DNA 
repair gene RAD51 which is associated with resistance 
to radiation, chemotherapeutic agents and tyrosine 
kinase inhibitor therapy [34-36]. Thus, enhanced DNA 
damage repair and more rapid cell replenishment could 
facilitate maintenance of the ALDHhiCD44hi population. 
Furthermore, TGFβ-dependent IL6 secretion has been 
shown to contribute to primary and acquired erlotinib 
resistance in lung cancer patients [37]. Our data showed 
ALDHhiCD44hi population had higher mRNA expression 
of the IL6 co-receptor IL6ST, suggesting TGFβ-induced 
resistance could reside mainly in TIC.
Expression profiling studies have shown 
enrichment of embryonic or tissue stem cell signatures 
is associated with increased risk of tumor metastasis, 
poor morphological differentiation and adverse patient 
outcomes, raising the possibility patient prognosis might 
be predicted by an appropriate TIC marker. Previous 
reports on the relevance of ALDH or CD44 single marker 
have yielded controversial information. For example, 
ALDH has been reported both as an adverse and a 
favorable prognostic indicator [21, 38]. For CD44, our 
previous study has shown a contradictory association 
with well-differentiated AD and a longer patient survival 
in lung adenocarcinomas [16]. In this study, there was 
no statistical evidence of global ALDH and CD44 co-
regulated expressions. Notably, when analysis was 
limited to tumors containing ALDH/CD44-coexpressing 
cells, those with a higher abundance of TIC was observed 
to associate with a shorter recurrence free survival (p = 
0.053). The finding suggested ALDH/CD44 co-expression 
could be a useful prognostic indicator and supported the 
relevance of these molecules as lung TIC marker. Some 
tumors lacked expression of either marker, suggesting 
other lung TIC indicators remain to be described. 
We have shown comprehensive in vitro, in vivo 
data as well as clinical support that the ALDHhiCD44hi 
compartment carries TIC capabilities and is the cellular 
mediator of drug resistance in lung cancer. These findings 
are useful in future studies addressing TIC-related cancer 
biology and development of TIC-targeting therapy.
MATERIALS AND METHODS
Cell lines 
Established human NSCLC cell lines were obtained 
from ATCC. PDCL were raised from resected lung cancers 
or malignant effusions and only 1st to 5th passage cells 
were used for study. Gefitinib or cisplatin-resistant (-GR or 
-CR) cells were generated by chronic graded exposure of 
parental cells to increasing doses of the respective drugs. 
Cells were maintained in RPMI-1640 (Life Technologies 
Inc.) or ACL4 with 10% FBS [22]. 
Flow cytometry and fluorescence activated cell 
sorting (FACS) 
ALDH activity was analyzed by the Aldefluor kit 
(Stem Cell Technologies) according to manufacturer’s 
instructions. Briefly, cells were suspended with 
activated Aldefluor substrate with or without 
diethylaminobenzaldehyde (DEAB) specific inhibitor 
as control at 37˚C for 30 minutes. CD44 expression 
was stained by anti-CD44-APC or anti-CD44-PE (BD 
Pharmingen) as previously described [16]. Cells were 
fixed and permeabilized (Invitrogen) before antibody 
incubation for NANOG (Cell signaling), POU5F1 
(Chemicon) and SOX2 (Cell signaling) analyses. 
Corresponding isotype-matched immunoglobulins were 
used as controls (BD Pharmingen). Non-viable cells were 
identified by propidium iodide inclusion. Mouse cells were 
gated out by Pacific blue-labeled anti-mouse CD31 and 
lineage and H-2Kd staining (BioLegend). Flow cytometry 
was performed using FACSCanto II (BD Biosciences) 
and figures were produced using FlowJo (Tree star). Cells 
showing ALDH and CD44 co-expression compared to 
staining controls were designated as ALDH+CD44+, those 
showing no expression of either marker as ALDH-CD44-, 
and those showing either marker only as ALDH+CD44- 
or ALDH-CD44+, respectively. For comparative studies 
between different ALDH/CD44 populations, cells showing 
the top/bottom 1 to 5% expression levels were freshly 
isolated by FACS using BD Aria (BD Biosciences) and 
designated accordingly as ALDHhiCD44hi, ALDHhiCD44lo, 
ALDHloCD44hi and ALDHloCD44lo populations. Each 
batch of cells was re-analyzed after collection to ensure a 
purity of > 90%. 
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Sphere formation assay
One thousand freshly isolated cells were cultured 
in an ultra-low plate (Costar) with serum-free medium 
containing FGF, EGF and IGF for 21 days as previously 
described [16]. 
Cell invasion assay
Cell invasion assay was performed using transwell® 
(Costar) coated with matrigel (BD Pharmingen) according 
to manufacturer’s instructions. 
Cell cycle analysis 
Freshly sorted cells were fixed in cold 70% ethanol, 
incubated in PBS buffer containing 50 µg/mL propidium 
iodide, 100 µg/mL RNAse A and 0.05% Triton X-100 at 
37˚C for 45 minutes and analyzed using flow cytometry. 
The proportion of cells in G0/G1, S and G2/M was 
calculated by FlowJo (Tree star).
Drug sensitivity and apoptosis assays
Drug sensitivity assay was performed by MTT test 
and apoptosis was quantified by Annexin V-FITC and PI 
staining as previously described [16]. 
Gene expression analysis
Gene mRNA expression was analyzed by 
quantitative RT-PCR (QPCR) (7900HT, Applied 
Biosystems) and SYBR green detection. Expressions of 
GAPDH and beta-2-microglobulin (B2M) were averaged 
and used as internal controls. Primers were listed in 
Supplementary Table S5. 
In vivo tumorigenicity and TKI response
All animal experiments were approved and 
performed according to guidelines by the Animal Ethics 
Committee, the University of Hong Kong. Briefly, freshly 
sorted cells mixed with an equal volume of matrigel (BD 
Pharmingen) were injected subcutaneously at the back 
of 6-week severe combined immunodeficiency (SCID) 
mice. For serial transplantation, the previous generation 
xenografts derived from the respective ALDH/CD44 
subsets were digested to obtain single cell suspensions, 
stained, subjected to FACS to isolate the parental subset 
and transplanted into subsequent recipients. To investigate 
the in vivo TKI response, mice bearing xenografts from 
HCC827 were subjected to intraperitoneal gefitinib 
(Selleck) injections at 50 mg/kg in 0.2 mL of 1% Tween 
80 five times per week for 4-5 weeks [39, 40]. Gefitinib 
was dissolved in DMSO; a mixture of 1% Tween 80 with 
an equal volume of DMSO was used as vehicle control. 
CD44 knockdown, ALDH, Hedgehog and Notch 
pathways inhibition
Small interfering RNA (siRNA) targeting human 
CD44 and non-targeting siRNA (Qiagen) were used 
for CD44 knockdown. Transfection was performed 
using Genemute (SignaGen Laboratories) according to 
the manufacturer’s instructions. DEAB (Sigma) was 
constituted in 100% ethanol and diluted in media to 100 
µM. The ALDEFLUOR Assay was used in conjunction 
with flow cytometry to assess ALDH activity following 
DEAB treatment. Cyclopamine (Selleck) or RO4929097 
(Selleck) was used for inhibition of Hedgehog or Notch 
pathway, respectively.
Immunohistochemistry (IHC) for ALDH and 
CD44 expression in clinical lung cancers 
Formalin-fixed paraffin-embedded tumor tissues 
from 193 surgically resected primary lung carcinomas 
without neoadjuvent therapy were arrayed on tissue micro-
array (TMA) with each case represented by 3 to 5 tumor 
cores. Tissues from fetal lung, reactive pulmonary lesions 
and a representative lung cancer were included in each 
TMA block for standardization. IHC for CD44 and ALDH 
were performed separately using anti-CD44 standard form 
(clone 156-3C11, 1:200 dilution, BiocareMedical) or 
anti-ALDH1A1 (1:1000 dilution, Abcam) as previously 
described [16]. Primary antibodies were replaced 
by SignalStain® Antibody Diluent (Cell Signaling 
Technology) in the negative controls. Expression levels 
were semi-quantitatively analyzed using an automated 
image capturing and analysis system (Aperio) [16]. 
Briefly, representative tumor areas in each tissue core 
excluding stroma, necrosis or inflammatory regions were 
gated on the scanned images. The staining intensities and 
cell abundance in each annotated area were computed 
using standard algorithms. Data from all tissue cores were 
integrated and a single score reflecting the abundance 
of ALDH or CD44-expressing cells, respectively, was 
assigned to each case. For ALDH/CD44-coexpresssion 
grading, only co-localized tumor cells with simultaneous 
ALDH and CD44 staining were counted. Tumor typing 
and pathological staging were according to W.H.O. criteria 
[41]. Patient outcomes were collated by the clinician in-
charge. 
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Statistical methods
Differences between groups were analyzed by 
student’s t test for continuous variables. Correlation 
between clinicopathological variables and ALDH or CD44 
expression were analyzed by χ2 test or Fisher Exact tests. 
Differences in patient survival were analyzed by log rank 
test and survival curves were drawn by Kaplan Meier 
method. Independent prognostic indicators for survival 
were analyzed by the Cox regression model. All statistical 
tests were analyzed by SPSS 18 for Windows (SPSS Inc., 
Chicago, IL). A 2-tailed p value of < 0.05 was considered 
as the threshold for statistical significance. 
ACKNOWLEDGEMENT
The study was supported by the Hong Kong 
Research Grants Council General Research Fund HKU 
783011/M, and the University of Hong Kong research 
grant 201209176184. The authors would like to thank 
LKS Faculty of Medicine at The University of Hong Kong 
for the Faculty Core Facility.
Disclosure of Potential Conflicts of Interest
The authors disclose no potential conflicts of 
interest.
REFERENCES
1. Pao W and Chmielecki J. Rational, biologically based 
treatment of EGFR-mutant non-small-cell lung cancer. Nat 
Rev Cancer. 2010; 10(11):760-774.
2. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho 
KK, Lam WK, Chiu SW, Girard L, Minna JD, Gazdar 
AF and Wong MP. Distinct epidermal growth factor 
receptor and KRAS mutation patterns in non-small cell 
lung cancer patients with different tobacco exposure and 
clinicopathologic features. Clinical cancer research : an 
official journal of the American Association for Cancer 
Research. 2006; 12(5):1647-1653.
3. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng 
LC, Ho KK, Au JS, Chung LP, Pik Wong M and University 
of Hong Kong Lung Cancer Study G. The EML4-ALK 
fusion gene is involved in various histologic types of lung 
cancers from nonsmokers with wild-type EGFR and KRAS. 
Cancer. 2009; 115(8):1723-1733.
4. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, 
Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, 
Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate 
AJ and Engelman JA. Mechanisms of acquired crizotinib 
resistance in ALK-rearranged lung Cancers. Science 
translational medicine. 2012; 4(120):120ra117.
5. Dienstmann R, Martinez P and Felip E. Personalizing 
therapy with targeted agents in non-small cell lung cancer. 
Oncotarget. 2011; 2(3):165-177.
6. Visvader JE and Lindeman GJ. Cancer stem cells: current 
status and evolving complexities. Cell Stem Cell. 2012; 
10(6):717-728.
7. Magee JA, Piskounova E and Morrison SJ. Cancer stem 
cells: impact, heterogeneity, and uncertainty. Cancer Cell. 
2012; 21(3):283-296.
8. Takebe N, Harris PJ, Warren RQ and Ivy SP. Targeting 
cancer stem cells by inhibiting Wnt, Notch, and Hedgehog 
pathways. Nature reviews Clinical oncology. 2011; 8(2):97-
106.
9. Garcia Campelo MR, Alonso Curbera G, Aparicio Gallego 
G, Grande Pulido E and Anton Aparicio LM. Stem cell and 
lung cancer development: blaming the Wnt, Hh and Notch 
signalling pathway. Clinical & translational oncology : 
official publication of the Federation of Spanish Oncology 
Societies and of the National Cancer Institute of Mexico. 
2011; 13(2):77-83.
10. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, 
Beer DG, Kalemkerian GP and Wicha MS. Notch Pathway 
Activity Identifies Cells with Cancer Stem Cell-like 
Properties and Correlates with Worse Survival in Lung 
Adenocarcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 
2013; 19(8):1972-1980.
11. Pacheco-Pinedo EC and Morrisey EE. Wnt and Kras 
signaling-dark siblings in lung cancer. Oncotarget. 2011; 
2(7):569-574.
12. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar 
S, Ma S, Soh BS, Sun LL, Tai BC, Nga ME, Bhakoo KK, 
Jayapal SR, Nichane M, Yu Q, Ahmed DA, Tan C, et al. 
Glycine decarboxylase activity drives non-small cell lung 
cancer tumor-initiating cells and tumorigenesis. Cell. 2012; 
148(1-2):259-272.
13. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, 
Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, 
Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, et 
al. Highly tumorigenic lung cancer CD133+ cells display 
stem-like features and are spared by cisplatin treatment. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2009; 106(38):16281-16286.
14. Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG, Lee 
JS, Lee SJ, Lee JC and Park MJ. Upregulation of CXCR4 
is functionally crucial for maintenance of stemness in drug-
resistant non-small cell lung cancer cells. Oncogene. 2013; 
32(2):209-221.
15. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens 
C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, 
Honorio S, Xie Y, Scaglioni PP, DiMaio JM, Gazdar AF, 
Shay JW, et al. Aldehyde dehydrogenase activity selects 
for lung adenocarcinoma stem cells dependent on notch 
signaling. Cancer research. 2010; 70(23):9937-9948.
16. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe 
Oncotarget 2013; 4:1710www.impactjournals.com/oncotarget
AD, Fink LM, Ma Y and Wong MP. Non-small cell lung 
cancer cells expressing CD44 are enriched for stem cell-like 
properties. PloS one. 2010; 5(11):e14062.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ 
and Clarke MF. Prospective identification of tumorigenic 
breast cancer cells. Proceedings of the National Academy 
of Sciences of the United States of America. 2003; 
100(7):3983-3988.
18. Kimura Y, Goi T, Nakazawa T, Hirono Y, Katayama K, 
Urano T and Yamaguchi A. CD44variant exon 9 plays an 
important role in colon cancer initiating cells. Oncotarget. 
2013; 4(5):785-791.
19. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, 
Vigneshwaran R, Gordon SA, Shimada Y and Wang TC. 
Identification of gastric cancer stem cells using the cell 
surface marker CD44. Stem cells (Dayton, Ohio). 2009; 
27(5):1006-1020.
20. Kumar PA, Hu Y, Yamamoto Y, Hoe NB, Wei TS, Mu D, 
Sun Y, Joo LS, Dagher R, Zielonka EM, Wang de Y, Lim 
B, Chow VT, Crum CP, Xian W and McKeon F. Distal 
airway stem cells yield alveoli in vitro and during lung 
regeneration following H1N1 influenza infection. Cell. 
2011; 147(3):525-538.
21. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, 
Wang H, Liu Z, Su Y, Stass SA and Katz RL. Aldehyde 
dehydrogenase 1 is a tumor stem cell-associated marker in 
lung cancer. Mol Cancer Res. 2009; 7(3):330-338.
22. Lam DC, Girard L, Suen WS, Chung LP, Tin VP, Lam 
WK, Minna JD and Wong MP. Establishment and 
expression profiling of new lung cancer cell lines from 
Chinese smokers and lifetime never-smokers. Journal of 
thoracic oncology : official publication of the International 
Association for the Study of Lung Cancer. 2006; 1(9):932-
942.
23. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, 
Hess DA and Allan AL. High aldehyde dehydrogenase 
and expression of cancer stem cell markers selects for 
breast cancer cells with enhanced malignant and metastatic 
ability. Journal of cellular and molecular medicine. 2009; 
13(8B):2236-2252.
24. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman 
JI, Prince ME, Wicha MS and Nor JE. Endothelial cell-
initiated signaling promotes the survival and self-renewal 
of cancer stem cells. Cancer research. 2010; 70(23):9969-
9978.
25. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, Yang J and Weinberg 
RA. The epithelial-mesenchymal transition generates cells 
with properties of stem cells. Cell. 2008; 133(4):704-715.
26. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston 
JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu 
J, MacSwords J, Cao Y, McLendon RE, Wang XF, 
Hjelmeland AB and Rich JN. Targeting interleukin 6 
signaling suppresses glioma stem cell survival and tumor 
growth. Stem cells (Dayton, Ohio). 2009; 27(10):2393-
2404.
27. Dean M, Fojo T and Bates S. Tumour stem cells and drug 
resistance. Nature reviews Cancer. 2005; 5(4):275-284.
28. Singh A and Settleman J. EMT, cancer stem cells and drug 
resistance: an emerging axis of evil in the war on cancer. 
Oncogene. 2010; 29(34):4741-4751.
29. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-
Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B 
and Menendez JA. Metformin-induced preferential killing 
of breast cancer initiating CD44+CD24-/low cells is 
sufficient to overcome primary resistance to trastuzumab in 
HER2+ human breast cancer xenografts. Oncotarget. 2012; 
3(4):395-398.
30. Sladek NE. Human aldehyde dehydrogenases: potential 
pathological, pharmacological, and toxicological impact. J 
Biochem Mol Toxicol. 2003; 17(1):7-23.
31. Ma I and Allan AL. The role of human aldehyde 
dehydrogenase in normal and cancer stem cells. Stem Cell 
Rev. 2011; 7(2):292-306.
32. Bourguignon LY, Spevak CC, Wong G, Xia W and Gilad 
E. Hyaluronan-CD44 interaction with protein kinase 
C(epsilon) promotes oncogenic signaling by the stem cell 
marker Nanog and the Production of microRNA-21, leading 
to down-regulation of the tumor suppressor protein PDCD4, 
anti-apoptosis, and chemotherapy resistance in breast 
tumor cells. The Journal of biological chemistry. 2009; 
284(39):26533-26546.
33. Bourguignon LY, Wong G, Earle C and Chen L. 
Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog 
promotes miR-302 expression leading to self-renewal, 
clonal formation, and cisplatin resistance in cancer stem 
cells from head and neck squamous cell carcinoma. The 
Journal of biological chemistry. 2012; 287(39):32800-
32824.
34. Bello VE, Aloyz RS, Christodoulopoulos G and Panasci LC. 
Homologous recombinational repair vis-a-vis chlorambucil 
resistance in chronic lymphocytic leukemia. Biochemical 
pharmacology. 2002; 63(9):1585-1588.
35. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki 
M, Blasiak J, Fishel R and Skorski T. Fusion tyrosine 
kinases induce drug resistance by stimulation of homology-
dependent recombination repair, prolongation of G(2)/M 
phase, and protection from apoptosis. Mol Cell Biol. 2002; 
22(12):4189-4201.
36. Ko JC, Ciou SC, Jhan JY, Cheng CM, Su YJ, Chuang SM, 
Lin ST, Chang CC and Lin YW. Roles of MKK1/2-ERK1/2 
and phosphoinositide 3-kinase-AKT signaling pathways in 
erlotinib-induced Rad51 suppression and cytotoxicity in 
human non-small cell lung cancer cells. Mol Cancer Res. 
2009; 7(8):1378-1389.
37. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted 
T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L 
and Sordella R. TGF-beta IL-6 axis mediates selective and 
Oncotarget 2013; 4:1711www.impactjournals.com/oncotarget
adaptive mechanisms of resistance to molecular targeted 
therapy in lung cancer. Proceedings of the National 
Academy of Sciences of the United States of America. 
2010; 107(35):15535-15540.
38. Dimou A, Neumeister V, Agarwal S, Anagnostou V, 
Syrigos K and Rimm DL. Measurement of aldehyde 
dehydrogenase 1 expression defines a group with better 
prognosis in patients with non-small cell lung cancer. The 
American journal of pathology. 2012; 181(4):1436-1442.
39. Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, Lubet RA 
and You M. Effect of an epidermal growth factor receptor 
inhibitor in mouse models of lung cancer. Mol Cancer Res. 
2006; 4(12):971-981.
40. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, 
Chan DC, Bemis L, Coldren C, Baron A, Zeng C, Franklin 
WA, Hirsch FR, Gazdar A, Minna J and Bunn PA, Jr. 
Antitumor activity of the epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) 
in non-small cell lung cancer cell lines correlates with 
gene copy number and EGFR mutations but not EGFR 
protein levels. Clinical cancer research : an official journal 
of the American Association for Cancer Research. 2006; 
12(23):7117-7125.
41. Travis W, Brambilla, E., Muller-Hermelink, H. and Harris, 
C. World Health Organization Classification of Tumors: 
Pathology and Genetics of tumors of the Lung, Pleura, 
Thymus and Heart. 2004.
